← Latest papers
📄 medicine

Associations of Serum Butyrylcholinesterase Activity With Hepatic Steatosis and Liver Stiffness in U.S. Adults: NHANES 2021–2023

In a cross-sectional analysis of U.S. adults from NHANES 2021–2023, higher serum butyrylcholinesterase activity was significantly associated with increased hepatic steatosis and liver stiffness, though its incremental value for clinical discrimination beyond standard risk factors was modest.

Original authors: Abdulrhman H. M. Muhaisen, Samah Rjoub, Wejdan Y Alquran, Elsayed Balbaa

Published 2026-11-17✓ Author reviewed ⓘ
📖 4 min read☕ Coffee break read

Original authors: Abdulrhman H. M. Muhaisen, Samah Rjoub, Wejdan Y Alquran, Elsayed Balbaa

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The liver is a tireless chemical factory inside the human body, filtering blood and storing energy. When too much fat builds up in this organ, a condition known as hepatic steatosis, it can set the stage for more serious disease. Doctors have long sought better ways to spot this fat accumulation early, often relying on blood tests that measure enzymes released when the liver is injured. However, there is another enzyme in the blood called butyrylcholinesterase that behaves differently. Instead of spiking when the liver is damaged, this enzyme often rises when the liver is full of fat but still functioning well. It acts as a subtle signal of the liver's metabolic state, reflecting the complex relationship between body weight, sugar processing, and fat storage. Understanding how this specific enzyme moves in the bloodstream could help researchers distinguish between a liver that is simply fatty and one that is becoming scarred or stiff, a distinction that is crucial for managing long-term health.

A recent study involving thousands of American adults has taken a closer look at this relationship using data from a massive national health survey. Researchers examined the blood of over 4,200 people, measuring the activity of butyrylcholinesterase and comparing it to two different ways of looking at the liver. The first method used sound waves to measure how much fat was present in the liver, while the second measured how stiff the liver tissue felt, which indicates scarring. The team found a clear and consistent pattern: people with higher levels of butyrylcholinesterase activity in their blood also had more fat in their livers. Specifically, for every standard increase in the enzyme's activity, the amount of fat detected in the liver rose significantly. This connection held true even when the researchers accounted for other factors like age, sex, body weight, diabetes, and alcohol use. The study suggests that this enzyme is a reliable marker for the presence of fatty liver, tracking the amount of fat accumulation across different groups of people.

In contrast to the clear link with liver fat, the relationship between this enzyme and liver stiffness was much less certain. While the enzyme levels rose steadily with fat, they did not show a consistent pattern with the stiffness of the liver tissue. The researchers found no strong evidence that higher enzyme levels meant the liver was becoming scarred or rigid. This distinction is important because it implies that butyrylcholinesterase is specifically tied to the metabolic process of fat storage rather than the structural damage of scarring. The study also looked at whether the enzyme's concentration in the blood mattered as much as its activity. They discovered that while both measures were related to liver fat, the actual activity of the enzyme provided a clearer picture than just the amount of protein present. This suggests that the chemical work the enzyme is doing is more relevant to the liver's condition than simply how much of it is floating in the blood.

Despite these strong associations, the researchers were careful to note the limits of what this finding means for everyday medical practice. While adding the enzyme measurement to standard health checks did improve the ability to detect fatty liver, the improvement was small. The enzyme helped identify a few more cases, but it did not transform the diagnosis or replace the need for other established tests. The study was also a snapshot in time, meaning it could show that the enzyme and liver fat move together, but it could not prove that one causes the other. It is possible that the fat in the liver triggers the rise in the enzyme, or that a third factor, such as metabolic health, drives both. The researchers also noted that the link between the enzyme and liver fat weakened slightly when they accounted for specific details about blood sugar and cholesterol, suggesting these factors are deeply intertwined.

Ultimately, this research paints a detailed picture of how a specific blood enzyme behaves in the context of modern metabolic health. It confirms that butyrylcholinesterase activity is a reliable companion to liver fat, rising as the liver accumulates more lipids. However, it does not appear to be a direct signal of liver scarring. The findings offer a clearer understanding of the liver's metabolic landscape, showing that different blood markers tell different parts of the story. While this enzyme is not yet a standalone tool for diagnosing liver disease, it adds a valuable piece to the puzzle, helping scientists and doctors see the difference between a fatty liver and a scarred one. Future studies will need to follow people over time to see if changes in this enzyme can predict who will develop serious liver problems, but for now, it stands as a significant clue in the ongoing effort to understand liver health.

Drowning in papers in your field?

Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.

Try Digest →